Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders

摘要

The present invention provides compounds, which, are novel antagonists for D₁ receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D₁ receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.